Read about the progress of the Vanderbilt research from the grant funded by AHCF….We made substantial progress toward completing the goals of Specific Aims 1 and 3 proposed last year. Some unforeseen obstacles hindered progress in Specific Aim 2, which includes development of an assay to screen for drugs that may reverse the functional defects caused by ATP1A3 mutations.
Click here for the full report:George-Final Progess Report-2013 grant